Covered recipient · General Payments record
BRITNEY N ONUMA
Allopathic & Osteopathic Physicians Pediatrics
General Payments · PY2022–2024
$661.58
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $297.15 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Seqirus USA Inc | $64.83 | 3 |
| SANOFI-AVENTIS U.S. LLC | $44.51 | 2 |
| Cranial Technologies, Inc | $36.61 | 2 |
| Corium, Inc. | $31.23 | 1 |
| Neos Therapeutics, LP | $29.20 | 2 |
| Supernus Pharmaceuticals, Inc. | $20.25 | 1 |
| Kaleo, Inc. | $20.13 | 1 |
| GlaxoSmithKline, LLC. | $17.51 | 1 |
| PFIZER INC. | $17.18 | 1 |
| Tris Pharma Inc | $15.70 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Corium, LLC | $31.23 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100073781 | CMS |
| Cranial Technologies, Inc | $20.65 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1082237294 | CMS |
| Cranial Technologies, Inc | $15.96 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1082237292 | CMS |
| GlaxoSmithKline, LLC. | $17.51 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116327996 | CMS |
| kaleo, Inc. | $20.13 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126623304 | CMS |
| Neos Therapeutics, LP | $14.60 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1082663043 | CMS |
| Neos Therapeutics, LP | $14.60 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1082665209 | CMS |
| PFIZER INC. | $17.18 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131793063 | CMS |
| SANOFI-AVENTIS U.S. LLC | $16.55 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139847730 | CMS |
| SANOFI-AVENTIS U.S. LLC | $27.96 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139847762 | CMS |
| Seqirus USA Inc | $24.09 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125638934 | CMS |
| Seqirus USA Inc | $18.34 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125638946 | CMS |
| Seqirus USA Inc | $22.40 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125638958 | CMS |
| Supernus Pharmaceuticals, Inc. | $20.25 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147876221 | CMS |
| Tris Pharma Inc | $15.70 | 08/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147212255 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.